

第19回 国際動脈硬化学会議

The 19th International Symposium on Atherosclerosis (ISA 2021)



Current Status and
Future Perspective of
HDL Functions

October, 26, 2021 (Tue) 12:40~13:40
Luncheon Seminar 4

Chair | 座長 Ken-ichi HIRATA Cardiovascular Medicine,
Kobe University Graduate School of Medicine

Speaker | 演者 Katsunori Ikekawi Division of Neurology, Anti-Aging,
and Vascular Medicine National Defense Medical College

Title | 演題 Current Status and Future Perspective of HDL Functions

Abstract | 抄録

Under statin era where statins reduced cardiovascular (CVD) risk by about 30%, attention has been shifted towards a next target to further reduce CVD risk. HDL, anti-atherogenic lipoprotein, considered to be a main target for that purpose, based on epidemiological evidence showing that HDL cholesterol (HDL-C) inversely associated with CVD morbidity and mortality. However, recent intervention trials using nicotinic acids or CETP inhibitors mostly failed to show CVD prevention. These findings, together with recent epidemiological studies showing that individuals with very high HDL-C rather associated with increased CVD risk, cast doubt on HDL raising strategy. Meanwhile, Rader DJ is one of the first to hypothesize that HDL function is a real player to modulate CVD risk.

Using cholesterol efflux capacity (CEC) assay representing a primary anti-atherogenic property of HDL, he showed that CEC is a novel risk factor for CVD (NEJM 2011, 2014). Plenty of clinical studies then confirmed CEC as CVD risk factor. However, since CEC is a cell-based assay using radiolabeled tracer, it has inherent shortcoming in terms of assay variation and standardization, whereby limiting wide use as clinical examination. Hirata and colleagues developed a novel assay, called cholesterol uptake capacity (CUC). CUC highly correlates with CEC and is cell-free, non-radioactive labeling, short step, therefore high-throughput assay using automated device. In this session, I will update clinical implication of HDL functions including CEC (CUC), anti-oxidation, anti-inflammation and discuss future perspective of novel therapies targeting HDL functions.

[共催] 第19回国際動脈硬化学会議/シスメックス株式会社
[Co-Host] The 19th International Symposium on Atherosclerosis (ISA 2021) & Sysmex Corporation

Hybrid Meeting
ハイブリッド開催

Onsite - 現地開催

+

Online - ウェブ開催
(Live streaming + On-demand)

会場へのアクセス

現地開催会場
国立京都国際会館
〒606-0001 京都府京都市左京区岩倉大鷲町422



Official HP

